BrainStorm Cell Therapeutics is developing innovative, autologous stem cell therapies for debilitating neurodegenerative diseases such as ALS. Its platform technology induces mesenchymal stem cells to secrete high levels of neuro-protective factors that promote the survival of neurons. We spoke to Chaim Lebovits, CEO of BrainStorm, about ALS, the company’s platform technology, how the company’s approach may be able to address a range of neurodegenerative diseases.
Stay Connected
Sign up for updates straight to your inbox.